Takeshi Ozeki

Dr. Takeshi Ozeki

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TKToshihiro Kishikawa
Toshihiro Kishikawa
YMYukihide Momozawa
Yukihide Momozawa
TOTakeshi Ozeki
Takeshi Ozeki
TMTaisei Mushiroda
Taisei Mushiroda
HIHidenori Inohara
Hidenori Inohara
YOYukinori Okada
Yukinori Okada
In the design of whole-genome sequencing (WGS) studies, sequencing depth is a crucial parameter to define variant calling accuracy and study cost, with no standard recommendations having been established. We empirically evaluated the variant calling accuracy of the WGS pipeline using ultra-deep WGS data (approximately 410×). We randomly sampled sequence reads and constructed a series of simulation WGS datasets with a variety of gradual depths (n = 54; from 0.05× to 410×). Next, we evaluated the genotype concordances of the WGS data with those in the SNP microarray data or the WGS data using all the sequence reads. In addition, we assessed the accuracy of HLA allele genotyping using the WGS data with multiple software tools (PHLAT, HLA-VBseq, HLA-HD, and SNP2HLA). The WGS data with higher depths showed higher concordance rates, and >13.7× depth achieved as high as >99% of concordance. Comparisons with the WGS data using all the sequence reads showed that SNVs achieved >95% of concordance at 17.6× depth, whereas indels showed only 60% concordance. For the accuracy of HLA allele genotyping using the WGS data, 13.7× depth showed sufficient accuracy while performance heterogeneity among the software tools was observed (the highest concordance of 96.9% was observed with HLA-HD). Improvement in HLA genotyping accuracy by further increasing the depths was limited. These results suggest a medium degree of the WGS depth setting (approximately 15×) to achieve both accurate SNV calling and cost-effectiveness, whereas relatively higher depths are required for accurate indel calling.

1 August 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
RNRyosuke Nakamura
Ryosuke Nakamura
TOTakeshi Ozeki
Takeshi Ozeki
NHNoriaki Hirayama
Noriaki Hirayama
ASAkihiro Sekine
Akihiro Sekine
TYTaiki Yamashita
Taiki Yamashita
EMEishin Morita
Eishin Morita

23 October 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
KHKeiko Hikino
Keiko Hikino
TOTakeshi Ozeki
Takeshi Ozeki
MKMasaru Koido
Masaru Koido
CTChikashi Terao
Chikashi Terao
YKYoichiro Kamatani
Yoichiro Kamatani
TMTaisei Mushiroda
Taisei Mushiroda

4 October 2019 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
KHKeiko Hikino
Keiko Hikino
TOTakeshi Ozeki
Takeshi Ozeki
MKMasaru Koido
Masaru Koido
CTChikashi Terao
Chikashi Terao
YKYoichiro Kamatani
Yoichiro Kamatani
TMTaisei Mushiroda
Taisei Mushiroda

1 January 2007 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
HYHaruko Yokoyama
Haruko Yokoyama
YYYoshikazu Yamamura
Yoshikazu Yamamura
TOTakeshi Ozeki
Takeshi Ozeki
TITatsuji Iga
Tatsuji Iga
YYYasuhiko Yamada
Yasuhiko Yamada
A Diskhaler is a dry powder type of inhaler that utilizes a breath controlled drug delivery system. The inspiratory flow rate of the patient would have a significant influence on the effects of drugs administered by a Diskhaler. Thus, we investigated the relationship between inspiratory flow rate and amount of drug delivered into the lungs when using a fluticasone propionate dry powder inhaler with a Diskhaler (FP-DH). To investigate the amount of drug inhaled, we used an inhalation simulator, which consisted of a flow recorder placed in a plastic air-tight box that covered the FP-DH equipped with a twin impinger and a vacuum pump. Drugs located in a plastic box, as well as the device, throat, and stage 1 and stage 2, were assayed by HPLC-UV, following in vitro inhalation at the various flow rates ranged from 18.7 to 77.3 l/min for 2 s. The relationship between peak inspiratory flow rate and amount of drug released from the device was analyzed. A positive linear correlation between the dose released from the device and amount of drug deposited in stage 2 was observed (r=0.899, p<0.001). The doses deposited in stage 2 were estimated to be 2.9 μg at a flow rate of 20 l/min, 6.6 μg at 30 l/min, 8.4 μg at 40 l/min, 10.1 μg at 60 l/min, and 11.3 μg at 90 l/min. It was suggested that the amount of drug in the lungs decreased along with a decrease in peak inspiratory flow rate when it was lower than 60 l/min. Our results were found to be very useful to estimate lung deposition by using peak inspiratory flow rate for administration planning, especially in patients with a flow rate of less than 60 l/min.

30 October 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KFKoya Fukunaga
Koya Fukunaga
ETEri Tsukagoshi
Eri Tsukagoshi
MKMaiko Kurata
Maiko Kurata
YMYoshiko Mizukawa
Yoshiko Mizukawa
HNHiroyuki Niihara
Hiroyuki Niihara
YSYoshiro Saito
Yoshiro Saito